Director, Clinical Development, Medical & Regulatory Affairs, Novo Nordisk, Inc
Sergey Zaets received MD degree from Moscow Medical Institute and PhD and DSc degrees from Bakoulev Center for Cardiovascular Surgery (Moscow, Russia), and used to work as a pediatric cardiac surgeon until relocation to the USA in 1999. During the years 1999-2005, performed research studies on red blood cell dysfunction in trauma-hemorrhagic shock, burn, gut ischemia, and pancreatitis at the UMDNJ - New Jersey Medical School. In 2005, joined Novo Nordisk Inc. Investigated the role of coagulation Factor XIII in prevention of multiple organ dysfunction after experimental trauma-hemorrhagic shock, burn, gut ischemia, and cardio-pulmonary bypass. Since 2009, is involved in clinical development of new recombinant factors to be in hemophilia and FXIII congenital deficiency.
Trauma-hemorrhagic shock, sepsis, coagulation disorders, congenital “open-heart” surgery. Author of more than 200 publications.